Jennifer Lew Sells 6,912 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew sold 6,912 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $2.92, for a total value of $20,183.04. Following the completion of the transaction, the chief financial officer now directly owns 77,770 shares in the company, valued at $227,088.40. The trade was a 8.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jennifer Lew also recently made the following trade(s):

• On Thursday, February 13th, Jennifer Lew sold 1,786 shares of Annexon stock. The stock was sold at an average price of $2.98, for a total transaction of $5,322.28.

Annexon Stock Performance

Shares of ANNX traded down $0.02 during trading hours on Thursday, reaching $2.83. 796,392 shares of the company traded hands, compared to its average volume of 1,392,680. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40. The stock has a market cap of $301.65 million, a P/E ratio of -2.70 and a beta of 1.07. The stock’s fifty day moving average is $4.33 and its 200 day moving average is $5.59.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ANNX shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon presently has an average rating of “Buy” and a consensus price target of $15.80.

Hedge Funds Weigh In On Annexon

Several large investors have recently added to or reduced their stakes in ANNX. State Street Corp increased its position in shares of Annexon by 116.6% during the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after purchasing an additional 2,068,294 shares during the period. Sio Capital Management LLC acquired a new stake in Annexon during the third quarter worth $8,484,000. Sphera Funds Management LTD. bought a new stake in Annexon in the 4th quarter valued at $6,377,000. Ameriprise Financial Inc. raised its stake in shares of Annexon by 483.6% in the 4th quarter. Ameriprise Financial Inc. now owns 926,642 shares of the company’s stock valued at $4,754,000 after buying an additional 767,869 shares in the last quarter. Finally, TFG Asset Management GP Ltd lifted its holdings in shares of Annexon by 78.5% during the 4th quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after acquiring an additional 615,645 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.